Want to join the conversation?
Pharmaceutical company $MYL said that it has agreed to acquire Meda, an international specialty pharmaceutical company via a recommended public offer and a transaction valued at $9.9Bil, including synergies and approx. $1.1Bil in EBITDA. This combination provides 2015 combined revenues of $11.8Bil.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.